You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Oral RAD51-inhibitor; refractory; B-cell; solid tumor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma Trial in United States (CYT-0851, CYT-0851 in combination with gemcitabine,

Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
Mar 7, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

Not yet recruiting
  • Solid Tumor, Adult
  • +2 more
  • (no location specified)
Dec 14, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor

Recruiting
  • Advanced Lymphoma
  • +13 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • New Haven, Connecticut
    Yale University Cancer Center LAO
Jun 29, 2022

Cancer Trial in United States (JTX-4014)

Active, not recruiting
  • Cancer
  • Denver, Colorado
  • +3 more
Sep 9, 2022

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

Active, not recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • Orelabrutinib
  • Recombinant humanized monoclonal antibody MIL62 injection
  • Bengbu, Anhui, China
  • +9 more
Nov 11, 2022

Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma Trial in United States (MQ719,

Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • +18 more
  • Basking Ridge, New Jersey
  • +6 more
May 18, 2023

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +9 more
  • Adelaide, Australia
  • +12 more
Jan 6, 2023

Solid Tumor Trial in San Antonio, Tyler, Spokane (TU2218 + Pembrolizumab)

Recruiting
  • Solid Tumor
  • TU2218 + Pembrolizumab
  • San Antonio, Texas
  • +2 more
Mar 26, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Transitional Cell Tumor, Hepatoblastoma, Liver Cancer Trial in Shanghai (PD-1 inhibitor)

Not yet recruiting
  • Transitional Cell Tumor
  • +4 more
  • PD-1 inhibitor
  • Shanghai, China
    Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Apr 3, 2022

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer Trial in

Completed
  • Acinar Cell Adenocarcinoma of the Pancreas
  • +4 more
  • sorafenib tosylate
  • +4 more
  • Aurora, Colorado
  • +1 more
Sep 8, 2022

Solid Tumor, B-Raf Mutation-Related Tumors Trial in Australia, United States (BGB-3245)

Recruiting
  • Solid Tumor
  • B-Raf Mutation-Related Tumors
  • Boston, Massachusetts
  • +4 more
Oct 25, 2022

Advanced Solid Tumor (Phase 1), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) Trial in United States (IMM-1-104)

Recruiting
  • Advanced Solid Tumor (Phase 1)
  • +4 more
  • Duarte, California
  • +4 more
Feb 2, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in China (abexinostat)

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Beijing, China
  • +22 more
Jan 26, 2023

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-219)

Recruiting
  • Acute Myeloid Leukemia
  • +12 more
  • Los Angeles, California
  • +6 more
Jun 1, 2022

B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor Trial in Edmonton, Toronto, Montréal (PCLX-001 treated)

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • Advanced Solid Tumor
  • PCLX-001 treated
  • Edmonton, Alberta, Canada
  • +2 more
Feb 28, 2022

Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • Orange, California
  • +13 more
Nov 7, 2022

Advanced Malignant Solid Tumor Trial in United States (Adavosertib, Carboplatin, Everolimus)

Completed
Has Results
  • Advanced Malignant Solid Neoplasm
  • Aurora, Colorado
  • +7 more
Apr 11, 2022

CNS Embryonal Tumor With Rhabdoid Features, CNS Embryonal Tumor, Not Otherwise Specified, CNS Ganglioneuroblastoma Trial in

Active, not recruiting
Has Results
  • Central Nervous System Embryonal Tumor With Rhabdoid Features
  • +14 more
  • Birmingham, Alabama
  • +23 more
Oct 7, 2022

Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer Trial (VLS-1488)

Not yet recruiting
  • Advanced Solid Tumor
  • +15 more
  • (no location specified)
Jun 2, 2023

Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)

Recruiting
  • Advanced Solid Tumor
  • +18 more
  • PT199
  • Anti-PD-1 monoclonal antibody
  • Huntersville, North Carolina
  • +2 more
Aug 10, 2022

Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma Trial in United States (MGC018, lorigerlimab)

Recruiting
  • Advanced Solid Tumor
  • +6 more
  • vobramitamab duocarmazine
  • lorigerlimab
  • Los Angeles, California
  • +7 more
Jan 10, 2023

Solid Tumor, NSCLC Metastatic Trial in Guanzhou (Ensartinib)

Recruiting
  • Solid Tumor
  • Non-Small Cell Lung Cancer Metastatic
  • Guanzhou, Guangdong, China
    Sun yat-sen Univerisity Cancer Center
Nov 22, 2021